Back to results
US 2012/0232093 A1Published application
Pyrazole derivatives as sigma receptor inhibitors
AssigneeLaboratorios Del Dr. Esteve, S.A.
InventorsRosa CUBERES-ALTISENT, Joerg HOLENZ
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula I having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
Claims23
1-26. (canceled)
A method of treating or preventing a sigma receptor mediated disease or condition, said method comprising administering to a patient in need of such a treatment or prevention a therapeutically effective amount of a compound of formula (I):
- wherein
- R1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
- R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
- Y is selected from substituted or unsubstituted phenyl or naphthyl;
- X is selected from:
- —CH2-Het-CHRx—,
- —CH2—CHRx-Het-,
- -Het-CH2—CHRx—,
- —CH2—CH2—CHRx—, or
- —CH2—CHRx—CH2—,
- with
- Het being NH, S or O,
- —CHRx— being
- wherein
- R5 and R6, identical or different, represent a hydrogen atom;
- an optionally substituted C1-4 alkyl group;
- an optionally substituted aryl group;
- an optionally substituted heteroaryl group;
- a C1-4 alkoxy group;
- a benzyl group;
- a phenethyl group;
- or
- form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted;
- or
- X is selected from:
- —CH2-Het-CHRx—,
- —CH2—CHRx-Het-,
- -Het-CH2—CHRx—,
- —CH2—CH2—CHRx—,
- —CH2—CHRx—CH2—,
- —CH2—CH2—NRx—, or
- —CH2—NRx—CH2—,
- with
- Het being NH, S or O,
- Rx, being a —(C═O)—R10;
- or a —(C═O)—O—R11 group;
- wherein
- R10 and R11 independently represent a hydrogen atom;
- a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl group;
- an optionally at least mono-substituted aryl group;
- an optionally at least mono-substituted heteroaryl group;
- an optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloalkyl group;
- a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-aryl group;
- a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-heteroaryl group;
- or a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-cycloalkyl group wherein the cycloalkyl group contains optionally at least one heteroatom as ring member;
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- t is 1, 2 or 3;
- R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
- optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.
46 more elements
Dependencies are inferred from the claim text.